US Pharma MarketingZealand, Roche topline a Phase 2 study for amylin drug, though Lilly remains an obstacle
Petrelintide reduced patients’ average body weight by up to 9.2%, compared to 2.0% among those who received placebo. Zealand Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo…
Zealand Pharma and Roche rolled out some mid-stage data for their amylin drug in obesity and diabetes, hoping to compete with Eli Lilly.
In a Phase 2 study, petrelintide reduced patients’ ...
Source: Endpoints News